The vaccination campaign against dengue for children and adolescents aged 10 to 14 in Araraquara, Brazil, has achieved less than the 90% coverage goal, prompting health officials to encourage more vaccinations.
In June 2024, a vaccination campaign was initiated in Araraquara, Brazil, targeting children and adolescents between the ages of 10 and 14 for dengue prevention. While all health clinics are offering the vaccine, coverage rates remain critically low, with only about 51.8% having received the first dose by early February, and a mere 27.64% having completed the two-dose regimen. This highlights the urgent need for increased public health efforts to encourage vaccination among this key demographic.
The vaccine, commercialized as Qdenga, is administered in two doses spaced three months apart. Studies by the manufacturer have demonstrated that after the second dose, the vaccine is approximately 80% effective against symptomatic dengue and significantly lowers the risk of severe disease, achieving over 90% protection against hospitalizations. The health department is emphasizing these benefits in their outreach campaigns to motivate both guardians and young individuals to participate in the vaccination efforts.
As dengue fever remains a significant public health concern, especially in hotspot areas like Araraquara, the need for high vaccination coverage is essential to control outbreaks and protect vulnerable populations. The Ministry of Health's target of at least 90% coverage is crucial to ensure herd immunity, and local health authorities are actively seeking strategies to increase participation in the ongoing vaccination program as case numbers continue to rise amidst a global backdrop of dengue outbreaks.
